Announced

CB Biotechnology to acquire Theratechnologies for up to $254m.

Synopsis

CB Biotechnology, an affiliate of pharmaceutical contract manufacturer Future Pak, agreed to acquire Theratechnologies, a Canadian biopharmaceutical company specializing in HIV and oncology treatments, for up to $254m. “This transaction is the result of a thorough and deliberate sale process aimed at maximizing value for our shareholders. Future Pak’s interest in acquiring Theratechnologies represents a vote of confidence in the company we’ve built, recognizing our achievements in bringing innovative medicines to patients and the outstanding contributions of our dedicated employees,” Frank A. Holler, Theratechnologies Chair of the Board of Directors.

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

All rights reserved. Copyright © 2025 Datasite